Fluidigm Corporation is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.
The company stated in the following article that they conduct pre-clinical trials of their drugs on animals.
“CD257 has been implicated in autoimmune disease based on animal model studies. BCMA, TACI, and BR3 have been identified as CD257 receptors.” Read the full article.
Fluidigm Corp. develops, manufactures, and markets microfluidic systems for growth markets such as single-cell genomics, applied genotyping and sample preparation for targeted resequencing, in the life science and agricultural biotechnology, or Ag-Bio, industries. Its proprietary microfluidic systems consist of instruments and consumables, including chips, assays and other reagents that are designed to overcome many of the limitations of conventional laboratory systems by integrating a vast number of fluidic components on a single microfabricated chip. The company was founded by Stephen R. Quake & Gajus V. Worthington on May 19, 1999 and is headquartered in South San Francisco, CA. [Source: MarketWatch]
Company Website: https://www.fluidigm.com